Change Control: How to Make Improvements Without Creating New Problems

Start with a clear proposal

A faster cleaning method might leave a different residue. A simpler instruction might remove an important check. An improvement can have a sensible objective and still create problems when its wider effects are missed.

Change control helps a team work through those effects before the changed process becomes routine. The useful questions are practical: What are we changing? What else could it affect? What evidence will support the decision? How will we know the improvement worked?

Consider a hypothetical manufacturing team that wants to replace the cleaning agent used on one product-contact mixing vessel. Its objective is to reduce cleaning time while maintaining the required cleaning performance.

That gives reviewers something concrete to evaluate. “Improve cleaning” does not.

Describe the current state, proposed state, reason, and intended outcome. Identify the equipment, products, locations, procedures, and systems within scope. State what is outside it.

For this example, changing the agent on one vessel does not automatically authorize its use on every vessel at the site. Keeping that boundary visible helps prevent a limited proposal from growing unnoticed.

Think about the last change you worked on. Was the scope clear from the start, or did it grow along the way? Share a non-confidential example in the video comments.

Keep change, deviation, and CAPA connected

These processes often interact, but they answer different questions.

• Change control: What proposed change should be evaluated and introduced under control?
• Deviation management: What departure or unexpected event occurred, and what assessment or investigation is needed?
• CAPA: What action addresses the cause and helps prevent recurrence or occurrence?

A CAPA may lead to a proposed process change. Link the records so that someone can follow the reasoning from the original problem to the selected action. See Deviation vs. CAPA and CAPA That Works: Moving Beyond Retraining.

A change record should not make an unapproved action look retrospectively approved. For US finished pharmaceuticals, written production and process-control procedures, including changes, require appropriate review and approval; deviations must be recorded and justified. Source: 21 CFR 211.100.

Ask what else could be affected

For the cleaning-agent proposal, the next discussion should go beyond whether the replacement removes visible soil faster.

The hypothetical team might ask:

• Could the agent affect vessel surfaces or seals?
• Does it require different handling, storage, or rinsing?
• Can the existing analytical approach assess relevant residues?
• Do instructions, sampling methods, records, or training need to change?
• What does the team performing the cleaning know that a desk review could miss?

Capture the reasoning behind the answers. An “unaffected” checkbox is more useful when a reviewer can understand why it was selected.

The depth of evaluation should reflect the risk. ICH Q10 calls for relevant expertise, risk-proportionate assessment, and consideration of regulatory implications. An internal label such as “minor” or “major” does not settle whether a filing, notification, or approval is required in a particular market. Source: ICH Q10, section 3.2.3.

Decide what evidence is needed

In the example, the team needs to establish whether existing cleaning evidence remains applicable and what additional work would support the new agent.

Depending on the assessed impact, that work might address cleaning performance, residues, material compatibility, or the changed operating instructions. A proposal does not need a complete revalidation simply because it is called a change; the required work should follow its actual impact and the applicable requirements.

EU GMP Annex 15 links change assessment to potential effects on product quality, validation, documentation, regulatory status, maintenance, and other connected systems. It also addresses cleaning validation. Source: EU GMP Annex 15, sections 10–11.

Define acceptance criteria before reviewing the results. For this hypothetical proposal, the team could plan to evaluate cleaning performance and compatibility alongside the intended time saving.

What evidence would you need before approving this cleaning-agent change? Share a non-confidential example in the video comments.

Make the transition unambiguous

A useful implementation plan makes the decision points clear:

1. Who owns each action?
2. What must be completed before routine use?
3. Who reviews the evidence?
4. Who authorizes the transition?
5. What would trigger a pause or further assessment?

For the vessel example, identify when the new instruction becomes effective, which agent is permitted, and how the previous agent will be controlled to prevent mix-ups. Make the approved instructions and correct materials available where the task happens.

Assess training needs before people perform the changed task. US finished-pharmaceutical requirements include written equipment-cleaning procedures that describe responsibilities, methods, equipment, and materials. Source: 21 CFR 211.67.

Temporary or urgent arrangements need clear boundaries too. A supply interruption does not establish that an alternative agent is suitable. Use the applicable process to define authorized scope, controls, responsible people, and the conditions for review or ending the arrangement.

Check the outcome, including unwanted effects

Suppose cleaning time improves, but rinse testing produces an unexpected result. The time saving does not resolve that finding. The team needs to assess it through the appropriate quality processes and reconsider its implications for the change.

Keep implementation evidence separate from evidence that the improvement worked. Updated documents, training records, and a completed checklist help show what was done. Performance data and relevant trends help show the result.

For this example, look at cleaning performance alongside time saved. Consider emerging problems such as repeated rinsing, equipment deterioration, or inconsistent execution. Choose evidence and a review period that fit the risk and actual use; a quiet week says little if the vessel was barely used. See CAPA Effectiveness Checks for related evidence-planning principles.

EU GMP Chapter 1 calls for planned changes to be evaluated and approved before implementation, with applicable regulatory requirements considered. It also calls for evaluation afterward to confirm the objectives were achieved without an unintended harmful effect on product quality. Source: EU GMP Chapter 1, section 1.4(xii–xiii).

A practical check before closure

Can the record explain:

• What changed and why?
• Which scope and conditions were approved?
• What evidence supported implementation?
• Whether the objective was achieved?
• How unexpected findings were addressed?
• Who owns any continuing monitoring?

Close the change through the approved process when the required evidence and reviews support closure. Routine process ownership continues afterward.

Which part of change control is most challenging for your team: impact assessment, implementation, or checking effectiveness? Share a non-confidential example in the video comments.

Keep comments non-confidential, without naming people, companies, or products.

The sequence is straightforward: define, assess, approve, implement, and evaluate. The quality of the reasoning determines how useful each step becomes.

Educational scope

This article is general educational content. The cleaning-agent scenario is hypothetical, not a validation protocol or mandatory template. The cited sources address pharmaceutical quality systems and specific GMP scopes; they are not a universal rulebook for every life-sciences sector. Apply the requirements relevant to your product, operation, markets, and approved quality system.